WEKO3
アイテム
{"_buckets": {"deposit": "61424731-74e5-4d3a-ae69-6c4e3dc7c8da"}, "_deposit": {"created_by": 3, "id": "21505", "owners": [3], "pid": {"revision_id": 0, "type": "depid", "value": "21505"}, "status": "published"}, "_oai": {"id": "oai:kindai.repo.nii.ac.jp:00021505", "sets": ["4613"]}, "author_link": ["43217"], "control_number": "21505", "item_8_biblio_info_21": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2020", "bibliographicIssueDateType": "Issued"}, "bibliographicPageEnd": "5", "bibliographicPageStart": "1", "bibliographic_titles": [{"bibliographic_title": "科学研究費助成事業研究成果報告書 (2019)"}]}]}, "item_8_date_19": {"attribute_name": "日付 作成日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2020-12-25", "subitem_date_issued_type": "Created"}]}, "item_8_description_25": {"attribute_name": "リンクURL", "attribute_value_mlt": [{"subitem_description": "https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-17K15032/", "subitem_description_type": "Other"}]}, "item_8_description_33": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "研究成果の概要(和文):本研究には16例のALK-TKIに耐性を獲得したEML4-ALK融合遺伝子陽性肺癌患者を登録。全例で耐性後に血液検体採取し、12例では耐性後に再生検を施行し組織採取ができた。10例で治療前後両方の腫瘍組織検体を集めており、収集した検体から抽出したDNAを用いて行った体細胞遺伝子変異解析から5つの既知のALK遺伝子の2次変異を検出した。2次耐性変異検出例の患者背景としては、男性、非喫煙又は軽喫煙者が多く、全例Alectinibの投与歴を有していた。2次耐性変異検出例では全例で後治療が施行されており、4例で第3世代ALK-TKIであるLorlatinibが投与され、全例で腫瘍縮小効果が得られた。研究成果の概要(英文):Between November 2016 and May 2019, 16 EML4-ALK fusion gene-positive patients were enrolled following disease progression on first- or second-generation ALK inhibitors. Blood samples were collected in all patients, and re-biopsy was performed in 12 patients. Paired samples of pre- and post-ALK-TKI treatment were collected in 10 patients and next-generation sequencing was performed. Among the 12 patients undergoing ALK-TKI-resistant biopsies, 6 (50.0%) had secondary mutations. The most common ALK resistance mutation was G1202R (2 cases), and the remaining ALK resistance mutations included: G1269A, L1196M, V1180L, and F1174L. The characteristics of patients with secondary mutations were mostly males (83.3%), non-smokers (50%), or light smokers (33.3%), and all patients pretreated with alectinib. Of the 4 patients (66.7%) with secondary mutations were treated with lorlatinib, a third-generation ALK-TKI, and all patients had a response to lorlatinib.", "subitem_description_type": "Abstract"}]}, "item_8_description_36": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "研究種目:若手研究(B); 研究期間:2017~2019; 課題番号:17K15032; 研究分野:臨床腫瘍学; 科研費の分科・細目:", "subitem_description_type": "Other"}]}, "item_8_description_37": {"attribute_name": "資源タイプ(WEKO2)", "attribute_value_mlt": [{"subitem_description": "Research Paper", "subitem_description_type": "Other"}]}, "item_8_description_41": {"attribute_name": "フォーマット", "attribute_value_mlt": [{"subitem_description": "application/pdf", "subitem_description_type": "Other"}]}, "item_8_publisher_14": {"attribute_name": "出版者 名前", "attribute_value_mlt": [{"subitem_publisher": "近畿大学"}]}, "item_8_text_10": {"attribute_name": "著者 役割", "attribute_value_mlt": [{"subitem_text_value": "研究代表者"}]}, "item_8_text_15": {"attribute_name": "出版社 カナ", "attribute_value_mlt": [{"subitem_text_value": "キンキダイガク"}]}, "item_8_text_16": {"attribute_name": "出版社 ローマ字", "attribute_value_mlt": [{"subitem_text_value": "Kinki Daigaku"}]}, "item_8_text_17": {"attribute_name": "出版年(from)", "attribute_value_mlt": [{"subitem_text_value": "2020"}]}, "item_8_text_53": {"attribute_name": "登録者(XooNIps)", "attribute_value_mlt": [{"subitem_text_value": "近畿大学中央図書館"}]}, "item_8_text_7": {"attribute_name": "著者(英)", "attribute_value_mlt": [{"subitem_text_language": "en", "subitem_text_value": "TANAKA, Kaoru"}]}, "item_8_text_8": {"attribute_name": "著者 所属", "attribute_value_mlt": [{"subitem_text_value": "近畿大学医学部; 講師"}]}, "item_8_text_9": {"attribute_name": "著者所属(翻訳)", "attribute_value_mlt": [{"subitem_text_value": "Kindai University"}]}, "item_8_version_type_12": {"attribute_name": "版", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_be7fb7dd8ff6fe43", "subitem_version_type": "NA"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "田中, 薫"}, {"creatorName": "タナカ, カオル", "creatorNameLang": "ja-Kana"}], "nameIdentifiers": [{"nameIdentifier": "43217", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "80548628", "nameIdentifierScheme": "NRID", "nameIdentifierURI": "https://nrid.nii.ac.jp/ja/search/?kw=80548628"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2021-03-15"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "17K15032seika.pdf", "filesize": [{"value": "320.7 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 320700.0, "url": {"label": "17K15032seika.pdf", "url": "https://kindai.repo.nii.ac.jp/record/21505/files/17K15032seika.pdf"}, "version_id": "5ffb7c23-094a-45f3-a638-6a79c6daac26"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "分子標的治療", "subitem_subject_scheme": "Other"}, {"subitem_subject": "ALK阻害剤", "subitem_subject_scheme": "Other"}, {"subitem_subject": "薬剤耐性", "subitem_subject_scheme": "Other"}, {"subitem_subject": "非小細胞肺癌", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "research report", "resourceuri": "http://purl.org/coar/resource_type/c_18ws"}]}, "item_title": "ALK融合遺伝子陽性非小細胞肺癌におけるALK-TKI耐性機序に関する研究", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "ALK融合遺伝子陽性非小細胞肺癌におけるALK-TKI耐性機序に関する研究", "subitem_title_language": "ja"}, {"subitem_title": "Research on mechanisms of acquired resistance to ALK-TKI in ALK fusion gene positive non-small cell lung cancer", "subitem_title_language": "en"}]}, "item_type_id": "8", "owner": "3", "path": ["4613"], "permalink_uri": "https://kindai.repo.nii.ac.jp/records/21505", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2021-03-15"}, "publish_date": "2021-03-15", "publish_status": "0", "recid": "21505", "relation": {}, "relation_version_is_last": true, "title": ["ALK融合遺伝子陽性非小細胞肺癌におけるALK-TKI耐性機序に関する研究"], "weko_shared_id": -1}
ALK融合遺伝子陽性非小細胞肺癌におけるALK-TKI耐性機序に関する研究
https://kindai.repo.nii.ac.jp/records/21505
https://kindai.repo.nii.ac.jp/records/21505ec64e012-3d46-4b5c-b3c9-8308b90e9c3c
名前 / ファイル | ライセンス | アクション |
---|---|---|
17K15032seika.pdf (320.7 kB)
|
|
Item type | 研究報告書 / Research Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2021-03-15 | |||||
タイトル | ||||||
言語 | ja | |||||
タイトル | ALK融合遺伝子陽性非小細胞肺癌におけるALK-TKI耐性機序に関する研究 | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | Research on mechanisms of acquired resistance to ALK-TKI in ALK fusion gene positive non-small cell lung cancer | |||||
著者 |
田中, 薫
× 田中, 薫 |
|||||
言語 | ||||||
言語 | jpn | |||||
キーワード | ||||||
主題 | 分子標的治療, ALK阻害剤, 薬剤耐性, 非小細胞肺癌 | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_18ws | |||||
資源タイプ | research report | |||||
著者(英) | ||||||
en | ||||||
TANAKA, Kaoru | ||||||
著者 所属 | ||||||
近畿大学医学部; 講師 | ||||||
著者所属(翻訳) | ||||||
Kindai University | ||||||
著者 役割 | ||||||
研究代表者 | ||||||
版 | ||||||
出版タイプ | NA | |||||
出版タイプResource | http://purl.org/coar/version/c_be7fb7dd8ff6fe43 | |||||
出版者 名前 | ||||||
出版者 | 近畿大学 | |||||
書誌情報 |
科学研究費助成事業研究成果報告書 (2019) p. 1-5, 発行日 2020 |
|||||
リンクURL | ||||||
内容記述タイプ | Other | |||||
内容記述 | https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-17K15032/ | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | 研究成果の概要(和文):本研究には16例のALK-TKIに耐性を獲得したEML4-ALK融合遺伝子陽性肺癌患者を登録。全例で耐性後に血液検体採取し、12例では耐性後に再生検を施行し組織採取ができた。10例で治療前後両方の腫瘍組織検体を集めており、収集した検体から抽出したDNAを用いて行った体細胞遺伝子変異解析から5つの既知のALK遺伝子の2次変異を検出した。2次耐性変異検出例の患者背景としては、男性、非喫煙又は軽喫煙者が多く、全例Alectinibの投与歴を有していた。2次耐性変異検出例では全例で後治療が施行されており、4例で第3世代ALK-TKIであるLorlatinibが投与され、全例で腫瘍縮小効果が得られた。研究成果の概要(英文):Between November 2016 and May 2019, 16 EML4-ALK fusion gene-positive patients were enrolled following disease progression on first- or second-generation ALK inhibitors. Blood samples were collected in all patients, and re-biopsy was performed in 12 patients. Paired samples of pre- and post-ALK-TKI treatment were collected in 10 patients and next-generation sequencing was performed. Among the 12 patients undergoing ALK-TKI-resistant biopsies, 6 (50.0%) had secondary mutations. The most common ALK resistance mutation was G1202R (2 cases), and the remaining ALK resistance mutations included: G1269A, L1196M, V1180L, and F1174L. The characteristics of patients with secondary mutations were mostly males (83.3%), non-smokers (50%), or light smokers (33.3%), and all patients pretreated with alectinib. Of the 4 patients (66.7%) with secondary mutations were treated with lorlatinib, a third-generation ALK-TKI, and all patients had a response to lorlatinib. | |||||
内容記述 | ||||||
内容記述タイプ | Other | |||||
内容記述 | 研究種目:若手研究(B); 研究期間:2017~2019; 課題番号:17K15032; 研究分野:臨床腫瘍学; 科研費の分科・細目: | |||||
資源タイプ(WEKO2) | ||||||
内容記述タイプ | Other | |||||
内容記述 | Research Paper | |||||
フォーマット | ||||||
内容記述タイプ | Other | |||||
内容記述 | application/pdf |